Egetis Therapeutics AB (publ) (EGTX.ST)
SEK 4.09
(1.11%)
SEK 4.09
(1.11%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -319.1 Million SEK | -65.81% |
| 2022 | -191 Million SEK | -87.44% |
| 2021 | -101.89 Million SEK | 42.99% |
| 2020 | -177.62 Million SEK | -192.01% |
| 2019 | -61.2 Million SEK | 28.0% |
| 2018 | - SEK | 3.34% |
| 2017 | -87.93 Million SEK | -130.06% |
| 2016 | -38.22 Million SEK | 12.78% |
| 2015 | -44.12 Million SEK | 9.18% |
| 2014 | -48.6 Million SEK | -89.12% |
| 2013 | -26.18 Million SEK | 24.63% |
| 2012 | -33.85 Million SEK | -110.11% |
| 2011 | -16.11 Million SEK | -324.16% |
| 2010 | -3.79 Million SEK | -182.73% |
| 2009 | -1.34 Million SEK | -140.21% |
| 2008 | -557.13 Thousand SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -74.9 Million SEK | 4.43% |
| 2024 Q1 | -70.1 Million SEK | 14.0% |
| 2023 FY | - SEK | -65.81% |
| 2023 Q2 | -78.6 Million SEK | -6.65% |
| 2023 Q1 | -73.7 Million SEK | 4.53% |
| 2023 Q3 | -85.2 Million SEK | -8.4% |
| 2023 Q4 | -81.7 Million SEK | 4.11% |
| 2022 Q1 | -28.1 Million SEK | 9.92% |
| 2022 FY | - SEK | -87.44% |
| 2022 Q4 | -77.2 Million SEK | -45.11% |
| 2022 Q3 | -53.2 Million SEK | -63.52% |
| 2022 Q2 | -32.53 Million SEK | -15.76% |
| 2021 Q2 | -33.17 Million SEK | -75.92% |
| 2021 Q3 | -18.17 Million SEK | 45.22% |
| 2021 Q4 | -31.19 Million SEK | -71.66% |
| 2021 Q1 | -18.86 Million SEK | 74.91% |
| 2021 FY | - SEK | 42.99% |
| 2020 Q2 | -33.7 Million SEK | 21.18% |
| 2020 FY | - SEK | -192.01% |
| 2020 Q4 | -75.18 Million SEK | -210.35% |
| 2020 Q1 | -42.76 Million SEK | -86.32% |
| 2020 Q3 | -24.22 Million SEK | 28.13% |
| 2019 Q1 | 22.93 Million SEK | 203.63% |
| 2019 FY | - SEK | 28.0% |
| 2019 Q2 | -29.35 Million SEK | -227.97% |
| 2019 Q3 | -31.83 Million SEK | -8.46% |
| 2019 Q4 | -22.95 Million SEK | 27.92% |
| 2018 Q3 | -18.84 Million SEK | 33.2% |
| 2018 Q4 | -22.13 Million SEK | -17.47% |
| 2018 FY | - SEK | 3.34% |
| 2018 Q1 | -15.81 Million SEK | 50.79% |
| 2018 Q2 | -28.21 Million SEK | -78.43% |
| 2017 FY | - SEK | -130.06% |
| 2017 Q4 | -32.12 Million SEK | -17.52% |
| 2017 Q3 | -27.33 Million SEK | -68.87% |
| 2017 Q2 | -16.18 Million SEK | -31.82% |
| 2017 Q1 | -12.28 Million SEK | -7.15% |
| 2016 Q1 | -6.84 Million SEK | 22.3% |
| 2016 FY | - SEK | 12.78% |
| 2016 Q4 | -11.46 Million SEK | -44.5% |
| 2016 Q3 | -7.93 Million SEK | 33.81% |
| 2016 Q2 | -11.98 Million SEK | -75.05% |
| 2015 Q3 | -11.43 Million SEK | 0.02% |
| 2015 FY | - SEK | 9.18% |
| 2015 Q1 | -12.15 Million SEK | 31.18% |
| 2015 Q2 | -11.43 Million SEK | 5.91% |
| 2015 Q4 | -8.81 Million SEK | 22.91% |
| 2014 Q2 | -12.61 Million SEK | -86.15% |
| 2014 Q1 | -6.77 Million SEK | 2.91% |
| 2014 Q4 | -17.65 Million SEK | -56.91% |
| 2014 Q3 | -11.25 Million SEK | 10.77% |
| 2014 FY | - SEK | -89.12% |
| 2013 Q2 | -6.03 Million SEK | 24.84% |
| 2013 FY | - SEK | 24.63% |
| 2013 Q4 | -6.97 Million SEK | -54.8% |
| 2013 Q3 | -4.5 Million SEK | 25.33% |
| 2013 Q1 | -8.03 Million SEK | 4.26% |
| 2012 Q2 | -10.54 Million SEK | -13.7% |
| 2012 FY | - SEK | -110.11% |
| 2012 Q4 | -8.38 Million SEK | -48.7% |
| 2012 Q3 | -5.64 Million SEK | 46.52% |
| 2012 Q1 | -9.27 Million SEK | -11.33% |
| 2011 Q2 | -2.48 Million SEK | 12.38% |
| 2011 Q1 | -2.83 Million SEK | -76.46% |
| 2011 Q4 | -8.33 Million SEK | -239.49% |
| 2011 FY | - SEK | -324.16% |
| 2011 Q3 | -2.45 Million SEK | 1.33% |
| 2010 Q2 | -754.61 Thousand SEK | -43.49% |
| 2010 Q1 | -525.89 Thousand SEK | 0.0% |
| 2010 Q4 | -1.6 Million SEK | -76.9% |
| 2010 FY | - SEK | -182.73% |
| 2010 Q3 | -909.33 Thousand SEK | -20.5% |
| 2009 FY | - SEK | -140.21% |
| 2008 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 13.242% |
| Camurus AB (publ) | 562.54 Million SEK | 156.724% |
| Mendus AB (publ) | -97.84 Million SEK | -226.125% |
| Lipum AB (publ) | -37.11 Million SEK | -759.668% |
| NextCell Pharma AB | -40.98 Million SEK | -678.575% |
| Simris Alg AB (publ) | -22.36 Million SEK | -1326.911% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -1767.774% |
| Active Biotech AB (publ) | -43.88 Million SEK | -627.095% |
| Amniotics AB (publ) | -27.14 Million SEK | -1075.625% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -2144.496% |
| BioArctic AB (publ) | 275.38 Million SEK | 215.873% |
| Cantargia AB (publ) | -284.31 Million SEK | -12.235% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -1529.807% |
| CombiGene AB (publ) | -35.33 Million SEK | -803.044% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | -126.551% |
| Genovis AB (publ.) | 64.57 Million SEK | 594.177% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | -177.703% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -761.873% |
| Intervacc AB (publ) | -68.98 Million SEK | -362.598% |
| Kancera AB (publ) | -61.88 Million SEK | -415.601% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -1091.427% |
| LIDDS AB (publ) | -39.67 Million SEK | -704.386% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -2536.319% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 1116.113% |
| OncoZenge AB (publ) | 7.26 Million SEK | 4491.687% |
| Saniona AB (publ) | -69.69 Million SEK | -357.852% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | -0.515% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | -13.143% |
| Xintela AB (publ) | -53.47 Million SEK | -496.772% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | -87.91% |
| Ziccum AB (publ) | -20.34 Million SEK | -1468.676% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 15955100.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | -34.293% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -15241.346% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -2275.847% |
| Corline Biomedical AB | -1.69 Million SEK | -18770.491% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | -84.106% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | -482.236% |
| Aptahem AB (publ) | -10 Million SEK | -3088.058% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 2863.01% |
| Fluicell AB (publ) | -25.91 Million SEK | -1131.381% |
| Biovica International AB (publ) | -119.5 Million SEK | -167.016% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -655.731% |
| AcouSort AB (publ) | -16.7 Million SEK | -1810.435% |
| Abliva AB (publ) | -93.6 Million SEK | -240.89% |
| 2cureX AB (publ) | -35.13 Million SEK | -808.185% |
| I-Tech AB | 30.34 Million SEK | 1151.574% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 55.343% |
| Cyxone AB (publ) | -20.41 Million SEK | -1463.143% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | -211.46% |
| Biosergen AB | 228 Thousand SEK | 140056.14% |
| Nanologica AB (publ) | -62.11 Million SEK | -413.691% |
| SynAct Pharma AB | -222.7 Million SEK | -43.286% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -627.526% |
| BioInvent International AB (publ) | -312.7 Million SEK | -2.044% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 103230.767% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 759879.995% |
| Oncopeptides AB (publ) | -231.62 Million SEK | -37.768% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -3521.002% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | -193.944% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -2682.283% |